Plo, Isabelle, 19..-....
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Isabelle Plo chercheuse
VIAF ID: 199860648 (Personal)
Permalink: http://viaf.org/viaf/199860648
Preferred Forms
-
100 0 _
‡a
Isabelle Plo
‡c
chercheuse
-
100 1 _
‡a
Plo, Isabelle,
‡d
19..-....
4xx's: Alternate Name Forms (5)
Works
| Title | Sources |
|---|---|
| Activation des voies anti-apoptotiques par les ligands de mort et les médicaments antitumoraux |
|
| AKT1 represses gene conversion induced by different genotoxic stresses and induces supernumerary centrosomes and aneuploidy in hamster ovary cells. |
|
| Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms |
|
| Anti-apoptic signaling pathways induced by death ligands and antitumors agents. |
|
| ATG2B and GSKIP: 2 new genes predisposing to myeloid malignancies |
|
| Caractérisation des anomalies d‘épissage dans un modèle cellulaire d'expression des mutations "driver" et additionnelle des Néoplasie Myéloprolifératives |
|
| Characterization of the effect of the loss of RBM22 on the pathogenesis of myelodysplastic neoplasms with deletion of chromosome 5q. |
|
| Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage. |
|
| Critical role of the HDAC6-cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect. |
|
| Crizotinib-Induced Immunogenic Cell Death in Non-Small Cell Lung Cancer. |
|
| CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner |
|
| CXCR4/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stress |
|
| Daunorubicin- and mitoxantrone-triggered phosphatidylcholine hydrolysis: implication in drug-induced ceramide generation and apoptosis |
|
| Demonstration of the leukemogenic effects of the HOXA9 transcription factor and validation of its inhibition by DNA ligands. |
|
| Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution |
|
| Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells |
|
| Disrupted filamin A/αβ interaction induces macrothrombocytopenia by increasing RhoA activity |
|
| DNA binding of the p21 repressor ZBTB2 is inhibited by cytosine hydroxymethylation. |
|
| Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis |
|
| A driver role for GABA metabolism in controlling stem and proliferative cell state through GHB production in glioma |
|
| Eltrombopag, a potent stimulator of megakaryopoiesis. |
|
| Emergence of a BCR-ABL translocation in a patient with the JAK2V617F mutation: evidence for secondary acquisition of BCR-ABL in the JAK2V617F clone. |
|
| Etude de la calréticuline dans les syndromes myéloprolifératifs : de la détermination de la charge allélique aux mécanismes de dégradation des variants protéiques |
|
| Étude de PRMT2 dans le développement leucémique et l'inflammation |
|
| Étude du rôle de HSF1 dans l'érythropoïèse |
|
| EZH2: a molecular switch of the MPN phenotype |
|
| Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors |
|
| Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients |
|
| Identification et caractérisation fonctionnelle de nouveaux acteurs de l'érythropoïèse normale et pathologique |
|
| Identification et mécanisme des facteurs de prédisposition à des néoplasmes myéloprolifératifs. |
|
| L’impact de JAK2V617F sur la différenciation érythroïdes terminale et l'électrophysiologie des globules rouges dans la Polyglobulie de Vaquez. |
|
| Impact des mutations germinales de GATA2 : du déficit fonctionnel au développement d'hémopathies myéloïdes |
|
| Impact of germline GATA2 mutations : from functional deficiency to development of myeloid neoplasms. |
|
| Impact of interferon on a triple positive polycythemia vera |
|
| Impact of the Expression of TRIAP1, Substrate of AIF/CHCHD4 Import Pathway, on Cancer Cell Proliferation and Metabolic Stress Response. |
|
| An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L. |
|
| Influence des cytokines immunitaires sur la mégacaryocytopoïèse et l'homéostasie des plaquettes sanguines : rôle de l'interleukine 21 |
|
| Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia |
|
| JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. |
|
| Kit signaling inhibits the sphingomyelin-ceramide pathway through PLC gamma 1: implication in stem cell factor radioprotective effect. |
|
| Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia. |
|
| Méthylations de l'histone H3 et contrôle épigénétique des propriétés des cellules souches de gliomes |
|
| Modélisation des néoplasmes myéloprolifératifs grâce aux cellules souches induites à la pluripotence (IPSC) |
|
| Molecular and genetic bases of myeloproliferative disorders: questions and perspectives. |
|
| Molecular characterization of myeloproliferative neoplasms and their transformation to acute myeloid leukemia. |
|
| Mort cellulaire immunogène induite par le crizotinib dans le cancer poumon non à petites cellules. |
|
| Mutations in the SRP54 gene cause severe congenital neutropenia as well as Shwachman-Diamond-like syndrome |
|
| Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy. |
|
| New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis. |
|
| Not just another kinase mutation! |
|
| p19 INK4d controls hematopoietic stem cells in a cell-autonomous manner during genotoxic stress and through the microenvironment during aging |
|
| P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis. |
|
| p53 at the crossroads of MPN treatment. |
|
| P53 deletion and NrasG12D cooperate for AML |
|
| Ph(-) myeloproliferative neoplasm red blood cells display deregulation of IQGAP1-Rho GTPase signaling depending on CALR/JAK2 status |
|
| Phosphatidylcholine‐derived phosphatidic acid and diacylglycerol are involved in the signaling pathways activated by docetaxel |
|
| Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients |
|
| Properties and biological roles of TET proteins during embryogenesis and in hematopoiesis |
|
| Quantitative Proteome Heterogeneity in Myeloproliferative Neoplasm Subtypes and Association with JAK2 Mutation Status. |
|
| Red blood cell and endothelial abnormalities in Polycythemia Vera : influence of the JAK2V617F mutation and role of hydroxycarbamide and interferon-alpha treatments. |
|
| Rôle de deux suppresseurs de tumeurs TET2 et P53 dans un contexte hématopoïétique |
|
| Rôle de la nouvelle isoforme d'épissage du gène von Hippel-Lindau dans la survenue d'érythrocytoses et de cancers du rein héréditaires |
|
| Rôle de la voie des Bone Morphogenetic Proteins dans la régulation des cellules souches leucémqiues dans la leucémie aiguë myeloïde. |
|
| Study of the mechanism of action of interferon alpha in classical myeloproliferative neoplasms. |
|
| Study of the role of HSF1 in erythropoiesis. |
|
| TET2 deficiency inhibits mesoderm and hematopoietic differentiation in human embryonic stem cells. |
|
| TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis |
|
| TET2 loss, a rescue of JAK2V617F HSCs. |
|
| TET2-mediated 5-hydroxymethylcytosine induces genetic instability and mutagenesis. |
|
| Therapeutic Potential of Activation of the Nuclear Receptor PPARgamma Pathway in Myelofibrosis. |
|
| Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. |
|
| Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands |
|
| Uncoupling of the Hippo and Rho pathways allows megakaryocytes to escape the tetraploid checkpoint |
|
| Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatment. |
|
